Product Code: PHA1221
The global Monoclonal Antibody Discovery and Analysis market is projected to grow at a CAGR of 9.0% by 2032.
“The Monoclonal Antibody Discovery and Analysis Market Report 2022-2032”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Growing Demand for Monoclonal Antibodies for Cancer Treatments
Monoclonal antibodies have demonstrated anticancer efficacy in a variety of cancers, thus they are not necessary for cancer therapy. Most toxicities, including fever, nausea, fatigue, changes in blood pressure, and bronchospasm, are self-limiting. The efficacy and timeliness of antibody-based diagnostic tests for a variety of disorders have both been enhanced by monoclonal antibodies. Clinical studies for more than 250 therapeutic monoclonal antibodies are now being conducted. These antibodies are used to treat cancer, autoimmune disorders, infectious diseases, and transplant patients. Inadequate effector functions, immunogenicity, and problems with pharmacokinetics have all been addressed through chimerization and humanization. As of November 1, 2021, 11 antibody treatments had been given first clearance for usage in either the European Union or the United States: Therapeutic antibodies will unavoidably continue to be a key component of drug research for many years to come. Regardless of the particular path used to produce the next generation of monoclonal antibody therapies, this is true.
What Questions Should You Ask before Buying a Market Research Report?
- How is the monoclonal antibody discovery and analysis market evolving?
- What is driving and restraining the monoclonal antibody discovery and analysis market?
- How will each monoclonal antibody discovery and analysis submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
- How will the market shares for each monoclonal antibody discovery and analysis submarket develop from 2022 to 2032?
- What will be the main driver for the overall market from 2022 to 2032?
- Will leading monoclonal antibody discovery and analysis markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
- Who are the leading players and what are their prospects over the forecast period?
- What are the monoclonal antibody discovery and analysis projects for these leading companies?
- How will the industry evolve during the period between 2020 and 2032? What are the implications of monoclonal antibody discovery and analysis projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the monoclonal antibody discovery and analysis market?
- Where is the monoclonal antibody discovery and analysis market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the monoclonal antibody discovery and analysis market today, and over the next 10 years:
- Our 437-page report provides 168 tables and 183 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the monoclonal antibody discovery and analysis market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising monoclonal antibody discovery and analysis prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.
Segments Covered in the Report:
Business Type
- Instruments Manufacturing
- Services & Solutions
- Ancillary Kits
Application
- Therapeutic Antibody Discovery
- Critical Reagent Antibody Discovery
- Biomarker and Diagnostic Antibody Discovery
- Research Antibody Discovery
Platform
- Hybridoma
- Humanization
- Phage Display
- Yeast Display
- Transgenic Rodents
Type
- Antigen Development
- Monoclonal Antibody Discovery
- Monoclonal Antibody Manufacturing
- Polyclonal Antibodies
- Label-free Kinetics Analysis
- Cell Banking
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:
North America
Europe
- Germany
- Spain
- United Kingdom
- France
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
Middle East & Africa
- Turkey
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Mexico
- Rest of Latin America
The report also includes profiles and for some of the leading companies in the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032, with a focus on this segment of these companies' operations.
Leading companies and the potential for market growth
- AbbVie Inc.
- Amgen Inc.
- Amneal Pharmaceutical LLC
- AstraZeneca
- Bayer AG
- BIOGEN
- Bristol- Myers Squibb company
- Eisai Co. Ltd
- Eli Lilly and Company
- F. Hoffman-La Roche Ltd.
- GlaxoSmithKline plc
- Johnson & Johnson Ltd.
- Lupin Limited
- Viatris Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- Zydus Lifesciences Limited
Overall world revenue for Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032 in terms of value the market will surpass US$5,610 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032 report help you?
In summary, our 430+ page report provides you with the following knowledge:
- Revenue forecasts to 2032 for Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032 Market, with forecasts for business type, platform, type, application and company size, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2032 for four regional and 20 key national markets - See forecasts for the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Middle East & Africa and Latin America. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 20 of the major companies involved in the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.
Table of Contents
1. Report Overview
- 1.1 Objectives of the Study
- 1.2 Introduction to Monoclonal Antibody Discovery & Analysis Market
- 1.3 What This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 Key Questions Answered by This Analytical Report
- 1.6 Who is This Report for?
- 1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
- 1.7.3.1 Primary Research
- 1.7.3.2 Secondary Research
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Reports
- 1.10 About
2 Executive Summary
3 Market Overview
- 3.1 Key Findings
- 3.2 Market Dynamics
- 3.2.1 Market Driving Factors
- 3.2.1.1 Launches of New Products
- 3.2.1.2 Growing Funding and Healthcare Costs
- 3.2.2 Market Restraining Factors
- 3.2.2.1 Price Limits
- 3.2.2.2 Pressures for Regulatory Approval
- 3.2.2.3 Induction of Biosimilars
- 3.2.3 Market Opportunities
- 3.2.3.1 Pandemic Offered Opportunities
- 3.2.3.2 Patent Exclusive Rights
- 3.3 Supply Chain
- 3.3.1 Immunotherapy Drug Supply Chain and Logistics Challenges
- 3.3.2 Immunotherapies' Vulnerability
- 3.3.3 A One-of-a-Kind Starting Point for T-Cell Treatments
- 3.3.4 The Supply Chain's Missing Manufacturing Link
- 3.3.5 Limited Availability
- 3.3.6 Keeping Command of the Immunotherapy Supply Chain
- 3.4 Cold chain
- 3.4.1 Agencies Favor Transport Simulation
- 3.4.2 Packaging Qualification for Thermal
- 3.4.3 Requests for Information Regarding the Schedule of Verification Studies
- 3.5 Recent Trends/ Developments
- 3.5.1 The FDA Received an Investigational New Drug (IND) Application for VRDN-002
- 3.5.2 Verseau Therapeutics, Inc. Reported on January 4, 2022, FDA Approval
- 3.5.3 A Veterinary mAb Receives FDA Approval for the First Time
- 3.5.4 Two Antibody Therapies Are in Seagen's Clinical Study Queue.
- 3.5.5 Spirea Raises £2.4 Million to Create Cancer-Specific Antibody Drug Conjugates
- 3.5.6 Exelixis, Inc. of California and BioInvent International AB of Swedenpartner to Create New Antibodies for Immuno-oncology Treatments
- 3.6 COVID-19 Impact Analysis
- 3.7 Porter's Five Forces Analysis
- 3.7.1 Supplier Power
- 3.7.2 Buyer Power
- 3.7.3 Competitive Rivalry
- 3.7.4 Threat from Substitutes
- 3.7.5 Threat of New Entrants
4 Monoclonal Antibody Discovery & Analysis Market Analysis by Business Type
- 4.1 Key Findings
- 4.2 Business Type Segment: Market Attractiveness Index
- 4.3 Monoclonal Antibody Discovery & Analysis Market by Business Type, 2022-2032 (US$ mn)
- 4.4 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn)
- 4.5 Instruments Manufacturing
- 4.6 Services & Solutions
- 4.6.1 Services
- 4.6.2 Solutions
- 4.7 Ancillary kits
5 Monoclonal Antibody Discovery & Analysis Market Analysis by Application
- 5.1 Key Findings
- 5.2 Application Segment: Market Attractiveness Index
- 5.3 Monoclonal Antibody Discovery & Analysis Market by Application, 2022-2032 (US$ mn)
- 5.4 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn)
- 5.5 Therapeutic Antibody Discovery
- 5.5.1 Transgenic Animal Leveraging Transgenic Animal Platforms for Antibody Discovery
- 5.5.2 Surrogate Antibodies
- 5.5.3 Drug Development
- 5.5.4 CAR-T Antibody Development
- 5.6 Critical Reagent Antibody Discovery
- 5.6.1 Anti-Idiotype Antibodies
- 5.6.2 Reagents and Tests for Immunogenicity and ADA
- 5.6.3 Antibodies and Assays for PK/PD/ADA
- 5.6.4 Studies for Potency
- 5.7 Biomarker and Diagnostic Antibody Discovery
- 5.8 Research Antibody Discovery
6 Monoclonal Antibody Discovery & Analysis Market Analysis by Platform
- 6.1 Key Findings
- 6.2 Platform Segment: Market Attractiveness Index
- 6.3 Monoclonal Antibody Discovery & Analysis Market by Platform, 2022-2032 (US$ mn)
- 6.4 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn)
- 6.5 Hybridoma
- 6.6 Humanization
- 6.7 Phage Display
- 6.8 Yeast display
- 6.9 Transgenic Rodents
7 Monoclonal Antibody Discovery & Analysis Market Analysis by Type
- 7.1 Key Findings
- 7.2 Type Segment: Market Attractiveness Index
- 7.3 Type Segment Market Attractiveness Index
- 7.4 Monoclonal Antibody Discovery & Analysis Market by Type, 2022-2032 (US$ mn)
- 7.5 Monoclonal Antibody Discovery & Analysis Market by Region, 2022-2032 (US$ mn)
- 7.6 Antigen Development
- 7.7 Monoclonal Antibody Discovery
- 7.8 Monoclonal Antibody Manufacturing
- 7.9 Polyclonal Antibodies
- 7.10 Label-Free Kinetics Analysis
- 7.11 Cell Banking
8 Monoclonal Antibody Discovery & Analysis Market Analysis by Region
- 8.1 Key Findings
- 8.2 Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
- 8.3 Monoclonal Antibody Discovery & Analysis Market Forecast, 2022-2032 (US$ mn)
- 8.4 Monoclonal Antibody Discovery & Analysis Market by Region
- 8.5 Monoclonal Antibody Discovery & Analysis Market by Business Type
- 8.6 Monoclonal Antibody Discovery & Analysis Market by Application
- 8.7 Monoclonal Antibody Discovery & Analysis Market by Platform
- 8.8 Monoclonal Antibody Discovery & Analysis Market by Type
9 North America Monoclonal Antibody Discovery & Analysis Market Analysis
- 9.1 Key Findings
- 9.2 North America Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
- 9.3 North America Monoclonal Antibodies Market by Value, 2022-2032 (US$ Mn)
- 9.4 Market Size Estimation and Forecast by Country
- 9.5 Market Size Estimation and Forecast by Business Type
- 9.6 Market Size Estimation and Forecast by Application
- 9.7 Market Size Estimation and Forecast by Platform
- 9.8 Market Size Estimation and Forecast by Type
- 9.9 U.S. Market Analysis
- 9.10 Canada Market Analysis
10 Europe Monoclonal Antibody Discovery & Analysis Market Analysis
- 10.1 Key Findings
- 10.2 Europe Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
- 10.3 Europe Monoclonal Antibodies Market by Value, 2022-2032 (US$ mn)
- 10.4 Market Size Estimation and Forecast by Country
- 10.5 Market Size Estimation and Forecast by Business Type
- 10.6 Market Size Estimation and Forecast by Application
- 10.7 Market Size Estimation and Forecast by Platform
- 10.8 Market Size Estimation and Forecast by Type
- 10.9 Germany Market Analysis
- 10.10 UK Market Analysis
- 10.11 France Market Analysis
- 10.12 Italy Market Analysis
- 10.13 Spain Market Analysis
- 10.14 Rest of Europe Market Analysis
11 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market Analysis
- 11.1 Key Findings
- 11.2 Asia-Pacific Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
- 11.3 Asia-Pacific Monoclonal Antibodies Market by Value, 2022-2032 (US$ mn)
- 11.4 Market Size Estimation and Forecast by Country
- 11.5 Market Size Estimation and Forecast by Business Type
- 11.6 Market Size Estimation and Forecast by Application
- 11.7 Market Size Estimation and Forecast by Platform
- 11.8 Market Size Estimation and Forecast by Type
- 11.9 China Market Analysis
- 11.10 India Market Analysis
- 11.11 Japan Market Analysis
- 11.12 South Korea Market Analysis
- 11.13 Australia Market Analysis
- 11.14 Rest of Asia-Pacific Market Analysis
12 Middle East and Africa Monoclonal Antibody Discovery & Analysis Market Analysis
- 12.1 Key Findings
- 12.2 Middle East and Africa Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
- 12.3 Middle East and Africa Monoclonal Antibodies Market by Value, 2022-2032 (US$ Mn)
- 12.4 Market Size Estimation and Forecast by Country
- 12.5 Market Size Estimation and Forecast by Business Type
- 12.6 Market Size Estimation and Forecast by Application
- 12.7 Market Size Estimation and Forecast by Platform
- 12.8 Market Size Estimation and Forecast by Type
- 12.9 South Africa Market Analysis
- 12.10 Saudi Arabia Market Analysis
- 12.11 Turkey Market Analysis
- 12.12 Rest of Middle East and Africa Market Analysis
13 Latin America Monoclonal Antibody Discovery & Analysis Market Analysis
- 13.1 Key Findings
- 13.2 Latin America Monoclonal Antibody Discovery & Analysis Market Attractiveness Index
- 13.3 Latin America Monoclonal Antibodies Market by Value, 2022-2032 (US$ mn)
- 13.4 Market Size Estimation and Forecast by Country
- 13.5 Market Size Estimation and Forecast by Business Type
- 13.6 Market Size Estimation and Forecast by Application
- 13.7 Market Size Estimation and Forecast by Platform
- 13.8 Market Size Estimation and Forecast by Type
- 13.9 Brazil Market Analysis
- 13.10 Mexico Market Analysis
- 13.11 Rest of Latin America Market Analysis
14 Competitive Landscape
- 14.1 Company Share Analysis
- 14.2 Key Business Strategy Analysis- Acquisition
- 14.3 Key Business Strategy Analysis- Agreement
- 14.4 Key Business Strategy Analysis- Alliance
- 14.5 Key Business Strategy Analysis- Collaboration
- 14.6 Key Business Strategy Analysis- Expansion
- 14.7 Key Business Strategy Analysis- Joint Venture
- 14.8 Key Business Strategy Analysis- New Product Launch
- 14.9 Key Business Strategy Analysis- Partnership
15 Company Profiles
- 15.1 AbbVie Inc.
- 15.1.1 Company Snapshot
- 15.1.2 Company Overview
- 15.1.3 Financial Analysis
- 15.1.3.1 Net Revenue, 2017-2021
- 15.1.3.2 Gross Profit, 2017-2021
- 15.1.3.3 R&D Expenses, 2017-2021
- 15.1.3.4 Regional Revenue Share
- 15.1.4 Product Benchmarking
- 15.1.5 Strategic Outlook
- 15.2 Amgen Inc.
- 15.2.1 Company Snapshot
- 15.2.2 Company Overview
- 15.2.3 Financial Analysis
- 15.2.3.1 Net Revenue, 2017-2021
- 15.2.3.2 Gross Profit, 2017-2021
- 15.2.3.3 R&D Expenses, 2017-2021
- 15.2.4 Product Benchmarking
- 15.2.5 Strategic Outlook
- 15.3 Amneal Pharmaceutical LLC
- 15.3.1 Company Snapshot
- 15.3.2 Company Overview
- 15.3.3 Financial Analysis
- 15.3.3.1 Net Revenue, 2017-2021
- 15.3.3.2 R&D Expenses, 2017-2021
- 15.3.4 Strategic Outlook
- 15.4 AstraZeneca
- 15.4.1 Company Snapshot
- 15.4.2 Company Overview
- 15.4.3 Financial Analysis
- 15.4.3.1 Net Revenue, 2017-2021
- 15.4.3.2 R&D Expenses, 2017-2021
- 15.4.3.3 Regional Revenue Share, 2021 (%)
- 15.4.4 Product Benchmarking
- 15.4.5 Strategic Outlook
- 15.5 Bayer AG
- 15.5.1 Company Snapshot
- 15.5.2 Company Overview
- 15.5.3 Financial Analysis
- 15.5.3.1 Net Revenue, 2017-2021
- 15.5.3.2 R&D Expenses, 2017-2021
- 15.5.3.3 Regional Revenue Share, 2021 (%)
- 15.5.4 Strategic Outlook
- 15.6 BIOGEN
- 15.6.1 Company Snapshot
- 15.6.2 Company Overview
- 15.6.3 Financial Analysis
- 15.6.3.1 Net Revenue, 2017-2021
- 15.6.3.2 R&D Expenses, 2017-2021
- 15.6.3.3 Regional Revenue Share, 2021 (%)
- 15.6.4 Product Benchmarking
- 15.6.5 Strategic Outlook
- 15.7 Bristol- Myers Squibb company
- 15.7.1 Company Snapshot
- 15.7.2 Company Overview
- 15.7.3 Financial Analysis
- 15.7.3.1 Net Revenue, 2017-2021
- 15.7.3.2 R&D Expenses, 2017-2021
- 15.7.3.3 Regional Revenue Share, 2021 (%)
- 15.7.4 Product Benchmarking
- 15.7.5 Strategic Outlook
- 15.8 Eisai Co.Ltd
- 15.8.1 Company Snapshot
- 15.8.2 Company Overview
- 15.8.3 Financial Analysis
- 15.8.3.1 Net Revenue, 2017-2021
- 15.8.3.2 R&D Expenses, 2017-2021
- 15.8.4 Product Benchmarking
- 15.8.5 Strategic Outlook
- 15.9 Eli Lilly and Company
- 15.9.1 Company Snapshot
- 15.9.2 Company Overview
- 15.9.3 Financial Analysis
- 15.9.3.1 Net Revenue, 2017-2021
- 15.9.3.2 R&D Expenses, 2017-2021
- 15.9.3.3 Regional Revenue Share, 2021 (%)
- 15.9.4 Product Benchmarking
- 15.9.5 Strategic Outlook
- 15.10 F. Hoffman-La Roche Ltd.
- 15.10.1 Company Snapshot
- 15.10.2 Company Overview
- 15.10.3 Financial Analysis
- 15.10.3.1 Net Revenue, 2017-2021
- 15.10.3.2 R&D Expenses, 2017-2021
- 15.10.3.3 Regional Revenue Share, 2021 (%)
- 15.10.4 Product Benchmarking
- 15.10.5 Strategic Outlook
- 15.11 GlaxoSmithKline plc
- 15.11.1 Company Snapshot
- 15.11.2 Company Overview
- 15.11.3 Financial Analysis
- 15.11.3.1 Net Revenue, 2018-2021
- 15.11.3.2 R&D Expenses, 2017-2021
- 15.11.3.3 Regional Revenue Share
- 15.11.4 Product Benchmarking
- 15.11.5 Strategic Outlook
- 15.12 Johnson & Johnson Ltd
- 15.12.1 Company Snapshot
- 15.12.2 Company Overview
- 15.12.3 Financial Analysis
- 15.12.3.1 Net Revenue, 2017-2021
- 15.12.3.2 R&D Expenses, 2017-2021
- 15.12.3.3 Regional Revenue Share, 2021 (%)
- 15.12.4 Strategic Outlook
- 15.13 Lupin Limited
- 15.13.1 Company Snapshot
- 15.13.2 Company Overview
- 15.13.3 Product Benchmarking
- 15.13.4 Strategic Outlook
- 15.14 Viatris Inc.
- 15.14.1 Company Snapshot
- 15.14.2 Company Overview
- 15.14.3 Financial Analysis
- 15.14.3.1 Net Revenue, 2017-2021
- 15.14.3.2 R&D Expenses, 2017-2021
- 15.14.4 Product Benchmarking
- 15.14.5 Strategic Outlook
- 15.15 Novartis AG
- 15.15.1 Company Snapshot
- 15.15.2 Company Overview
- 15.15.3 Financial Analysis
- 15.15.3.1 Net Revenue, 2017-2021
- 15.15.3.2 R&D Expenses, 2017-2021
- 15.15.3.3 Regional Revenue Share, 2021 (%)
- 15.15.4 Product Benchmarking
- 15.15.5 Strategic Outlook
- 15.16 Pfizer Inc.
- 15.16.1 Company Snapshot
- 15.16.2 Company Overview
- 15.16.3 Financial Analysis
- 15.16.3.1 Net Revenue, 2017-2021
- 15.16.3.2 Regional Revenue Share, 2021 (%)
- 15.16.4 Strategic Outlook
- 15.17 Regeneron Pharmaceuticals Inc
- 15.17.1 Company Snapshot
- 15.17.2 Company Overview
- 15.17.3 Financial Analysis
- 15.17.3.1 Net Revenue, 2017-2021
- 15.17.3.2 R&D Expenses, 2017-2021
- 15.17.4 Product Benchmarking
- 15.17.5 Strategic Outlook
- 15.18 Sanofi S.A.
- 15.18.1 Company Snapshot
- 15.18.2 Company Overview
- 15.18.3 Financial Analysis
- 15.18.3.1 Net Revenue, 2017-2021
- 15.18.3.2 R&D Expenses, 2017-2021
- 15.18.3.3 Regional Revenue Share, 2021 (%)
- 15.18.4 Product Benchmarking
- 15.18.5 Strategic Outlook
- 15.19 Teva Pharmaceutical Industries Ltd.
- 15.19.1 Company Snapshot
- 15.19.2 Company Overview
- 15.19.3 Financial Analysis
- 15.19.3.1 Net Revenue, 2017-2021
- 15.19.3.2 R&D Expenses, 2017-2021
- 15.19.3.3 Regional Revenue Share, 2021 (%)
- 15.19.4 Strategic Outlook
- 15.20 Zydus Lifesciences Limited
- 15.20.1 Company Snapshot
- 15.20.2 Company Overview
- 15.20.3 Product Benchmarking
- 15.20.4 Strategic Outlook
16 Conclusion and Recommendations
- 16.1 Concluding Remarks from
- 16.2 Recommendations for Market Players